ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

10:30AM-12:30PM: Abstract Number: 0066

RA-required synovial tissue-resident monocyte lineage cells are comprised of three distinct subpopulations.

(0049–0066) Rheumatoid Arthritis – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 0478

Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis

(0470–0505) Rheumatoid Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0390

Radiographic Assessment in Juvenile Spondyloarthritis: Evaluating the axJSpA Criteria Using Radiographs Alone Versus MRI

(0387–0429) Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0771

Radiographic Knee Osteoarthritis and Corticosteroid Injection Use: The Moderating Role of Physical Activity

(0765–0771) Orthopedics, Low Back Pain, & Rehabilitation Poster

10:30AM-12:30PM: Abstract Number: 0524

Radiographic progression in sacroiliac joints in five years follow up in non-radiographic axial spondyloarthritis patients and the predictive factors

(0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0552

Radiographic Sacroiliitis Progression in Psoriatic Arthritis

(0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0261

Randomized Confirmatory Basket Trial: Performance Evaluation of a Simulated Application Example in Rare Disease Using Real World Data

(0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0533

Reactive Arthritis Transcriptomics: Enriched Enterobacteriaceae-related Pathways in Synovial Fluid and in Blood is Associated with Drug-free Remission

(0522–0553) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0648

Real World Comparative Use of Anifrolumab in Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A Multicenter Cohort Study

(0641–0670) Systemic Lupus Erythematosus – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0554

Real world experience with generic Tofacitinib in Axial Spondyloarthritis from North India

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0738

Real World Steroid Burden, Treatment Patterns, and Rheumatologists’ Perceptions on Advanced Therapy in Giant Cell Arteritis

(0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0726

Real-World Avacopan Use in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Insights from United States Claims Data on Outcomes and Adherence

(0711–0730) Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0513

Real-world Clinical and Diagnostic Features of Patients with Isolated Anti-SSB Antibodies Compared to Those with Combination Anti-SSA and Anti-SSB Antibodies

(0506–0521) Sjögren’s Disease – Basic & Clinical Science Poster I: Etiology, Pathogenesis, Diagnosis

10:30AM-12:30PM: Abstract Number: 0502

Real-World Comparative Safety of Tocilizumab and Sarilumab in Rheumatoid Arthritis: A Multi-Center Observational Study

(0470–0505) Rheumatoid Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0661

Real-world Effectiveness and Usage of Voclosporin: Data from the Enlight-LN Registry

(0641–0670) Systemic Lupus Erythematosus – Treatment Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].